All In Biotech

NDA 017443 · Ph Health

Dantrium

Dantrolene Sodium · Oral

NovelPriority review

Last checked: Nov 19, 2026Latest source record: Jul 8, 2015 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1974

Jan 15, 1974

Approved uses

1

Original approval plus efficacy supplements

Registered trials

12

4 Phase 3, 1 recruiting

FAERS reports

1,138

998 serious, 124 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

Dantrolene sodium has a potential for hepatotoxicity, and should not be used in conditions other than those recommended. Symptomatic hepatitis (fatal and non-fatal) has been reported at various dose levels of the drug. The incidence reported in patients taking up to 400 mg/day is much lower than in those taking doses of 800 mg or more per day. Even sporadic short courses of these higher dose levels within a treatment regimen markedly increased the risk of serious hepatic injury. Liver dysfunction as evidenced by blood chemical abnormalities alone (liver enzyme elevations) has been observed in patients exposed to dantrolene sodium for varying periods of time. Overt hepatitis has occurred at varying intervals after initiation of therapy, but has been most frequently observed between the third and twelfth month of therapy. The risk of hepatic injury appears to be greater in females, in...

What it is approved for

From the label in effect Nov 11, 2026.

INDICATIONS AND USAGE In Chronic Spasticity: Dantrolene sodium is indicated in controlling the manifestations of clinical spasticity resulting from upper motor neuron disorders (e.g., spinal cord injury, stroke, cerebral palsy, or multiple sclerosis). It is of particular benefit to the patient whose functional rehabilitation has been retarded by the sequelae of spasticity. Such patients must have presumably reversible spasticity where relief of spasticity will aid in restoring residual function. Dantrolene sodium is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders. If improvement occurs, it will ordinarily occur within the dosage titration (see DOSAGE AND ADMINISTRATION ), and will be manifested by a decrease in the severity of spasticity and the ability to resume a daily function not quite attainable without dantrolene sodium. Occasionally, subtle but meaningful improvement in spasticity may occur with dantrolene sodium therapy. In such instances, information regarding improvement should be solicited from the patient and those who are in constant daily contact and attendance with him. Brief withdrawal of dantrolene sodium for a period of 2 to 4 days will frequently demonstrate exacerbation of the manifestations of spasticity and may serve to confirm a clinical impression. A decision to continue the administration of dantrolene sodium on a long-term basis is justified if introduction of the drug into the patient's regimen: produces a significant reduction in painful and/or disabling spasticity such as clonus, or permits a significant reduction in the intensity and/or degree of nursing care required, or rids the patient of any annoying manifestation of spasticity considered important by the patient himself. In Malignant...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 15, 1974 Original approval · Type 1 - New Molecular Entity · priority review
3 products under this application
  • DANTRIUM · DANTROLENE SODIUM 50MG · CAPSULE, ORAL · Prescription · TE AB
  • DANTRIUM · DANTROLENE SODIUM 25MG · CAPSULE, ORAL · Prescription · TE AB
  • DANTRIUM · DANTROLENE SODIUM 100MG · CAPSULE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Dantrolene" as an intervention, any sponsor and status, largest first.

All 12 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • neuroleptic malignant syndrome79
  • pyrexia63
  • pneumonia61
  • asthenia59
  • drug ineffective59
  • respiratory failure59
  • off label use54
  • urinary tract infection52
  • vomiting52
  • diarrhoea49
  • muscular weakness45
  • nausea45

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200445
200547
200654
200749
200859
200962
201061
201181
201283
201373
201443
201546
201663
201757
201845
201953
202042
202131
202236
202335
202427
202530
202616

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Dantrium (Dantrolene Sodium)

2024 spending

$8K

Beneficiaries

n/a

39 claims

Per beneficiary

n/a

$1.02 per unit

View as table
YearSpending
2020$29,516
2021$26,804
2022$17,162
2023$9,844
2024$7,941

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 91 on PubMed

Sponsor: Ph Health

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.